Darren Sigal, MD, is a nationally recognized translational and clinical investigator and GI oncologist. His clinical focus includes pancreatic cancer, colorectal cancer, and less common malignancies including cholangiocarcinoma and neuroendocrine tumors.
In addition to his clinical work, Dr. Sigal has led and contributed to numerous clinical trials focused on advancing treatment for gastrointestinal cancers. His research focuses on novel therapeutics, immune therapies, tumor microenvironment, and predictive biomarkers. He is particularly passionate about translating emerging scientific discoveries into novel treatment options for patients facing difficult-to-treat cancers.
Dr. Sigal’s expertise and vision bring powerful momentum to the OSF Breakthrough Treatment Center. His deep experience in investigator-initiated trials, early-phase research, and translational science will help shape a next-generation program focused on delivering innovative therapies to patients with rare and complex cancers. His collaborative approach will also help expand partnerships and trial opportunities across the OSF mission and beyond.
Dr. Sigal has over 50 peer-reviewed manuscripts that have been published in leading oncology journals, including Cancer Cell, Journal of Clinical Oncology, Nature Medicine, Lancet Oncology, and others. He has been an early and key advisor to multiple biotechnology companies and served as the chair of the Scientific Advisory Board for Celularity. In collaboration with scientific colleagues Dr. Sigal helped identify a potential new therapy for colon cancer.
He believes that the best treatment plans are built not only on the latest medical advances, but also on a deep understanding of each patient’s goals and well-being. His care philosophy centers on combining innovative science with compassionate, individualized care.
Dr. Sigal received his medical degree UCLA. He completed his residency in internal medicine at UC Davis and his hematology/oncology fellowship at Scripps Clinic. He is board certified in internal medicine and medical oncology.
In addition to his work with OSF, Dr. Sigal continues to serve as director of GI Oncology at Scripps Cancer Center/Scripps Clinic and the associate division head of hematology and oncology at Scripps Clinic in San Diego, where he leads multiple research programs.